c-erbB-2、bcl-2、bax和p53在大肠癌中的表达及其临床意义
|
摘要
目的:通过检测大肠癌与癌旁组织中c-erbB-2、bcl-2、bax和p53蛋白的表达,分析其在大肠癌中的表达及其临床意义。
材料与方法:2007年12月至2008年3月,辽宁省肿瘤医院大肠科手术切除的大肠癌标本75例,男44例,女31例,年龄30-78岁,平均年龄54±4.6岁。术前明确临床分期,入院前均未行放、化疗及免疫等抗肿瘤治疗,无二次手术史。取癌组织和癌旁组织(距癌组织超过5 cm)各1份,经免疫组织化学方法(S-P法)检测癌组织及癌旁组织中c-erbB-2、bcl-2、bax和p53蛋白的表达。采用卡方检验分析实验数据,P<0.05认为有统计学差异。
结果:c-erbB-2蛋白主要表达在癌组织细胞膜,呈现明显棕黄色颗粒,其表达阳性率为50.7 % (38/ 75),癌旁组织无表达;bcl-2蛋白表达在癌组织及癌旁组织的细胞浆及细胞膜均呈阳性表达,表现为棕黄色颗粒,呈灶性或弥漫分布,其阳性率分别为61.3% (46/ 75), 10.7% (8/ 75);bax蛋白表达在癌组织及癌旁组织的细胞浆呈阳性表达,表现为细胞浆出现棕黄色颗粒,呈弥漫性或灶性分布,阳性率为46.7 % (35/ 75), 81.3% (61/ 75);p53蛋白主要表达于细胞核,呈清晰棕色,阳性率为52.0%(39/ 75),癌旁组织无表达。统计分析显示:c-erbB-2阳性表达与肿瘤的大小有显著性差异,与年龄、性别、肿瘤的组织类型、浸润深度、大体分型之间无差异; bcl-2蛋白表达与大肠癌患者的淋巴结转移、Dukes分期有显著性差异,与年龄、性别、肿瘤的组织类型、浸润深度、大体分型之间无差异;bax和p53蛋白表达与大肠癌的各项临床指标无显著差异。癌组织与癌旁组织间四种基因产物表达的差异均具有显著性。
结论:1,c-erbB-2阳性表达与肿瘤的大小有显著性差异,与年龄、性别、肿瘤的组织类型、浸润深度、大体分型之间无差异; 2,bcl-2蛋白表达与大肠癌患者的淋巴结转移、Dukes分期有显著性差异,与年龄、性别、肿瘤的组织类型、浸润深度、大体分型之间无差异;3,bax和p53蛋白表达与大肠癌的各项临床指标无显著差异;4,癌组织与癌旁组织间四种基因产物表达的差异均具有显著性。
Objective: To analyze the expression and clinical significance of c-erbB-2、bcl-2、bax and p53 in colorectal cancer by detecting their expression in cancerous and adjacent tissues(> 5cm from the cancerous tissue).
Methods: Examples of 75 cases of colorectal cancer who were treated in tumor hospital of Liaoning province from December 2007 to March 2008 ,Male 44,female 31,aged from 30 to78 years old and 54±4.6 for average. Each part respectively in cancerous and adjacent tissues (> 5cm from the cancerous tissue). The clinical stages were identified prior to operation. All patients have not received any treatment before. The expression of c-erbB-2、bcl-2, bax and p53 protein in all case were detected by immune histochemistry (S-P).The photographs of S-P were taken by microscope and the data were examined by chi-square test .
Results: The positive expression of c-erbB-2 protein in this group of 75 cases of cancerous tissues was 50.7 % (38/75), with performance of yellowish brown pellet in the cell membrane.adjacent tissues was negative;The positive expression of bcl-2 protein in this group of 75 cases of cancerous tissues was 61.3% (46/ 75), Adjacent tissues was 10.7% (8/ 75) ,with performance of yellowish brown pellet in cytoplasma and cell membrane, distribution of focus or diffuse; The positive expression of bax protein in this group of 75 cases of cancerous tissues was 46.7 % (35/ 75), adjacent tissues was 81.3% (61/ 75), existing in the form of the yellowish brown pellet in the cytoplasma, distribution of focus or diffuse. The positive expression of p53 protein in this group of 75 cases of cancerous tissues was 52.0%(39/ 75), adjacent tissues was negative ,mainly located in the cell nucleus,with clear brown color of cell nucleus; The statistical analysis demonstrated the expression of c-erbB-2 had no significant differences with age、gender、and tissue type, only had significant differences with size ( P<0.05 ) ;Expression of bcl-2 had significant differences with metastasis of lymph node, Dukes' staging(P<0.05); The expression of bax and the p53 protein had no significant differences with the clinical index of colorectal cancer (P > 0. 05); the four gene expressions had a positive rate between cancerous and adjacent tissues (P<0.05).
Conclusion:
1, The expression of c-erbB-2 had no significant differences with age、gender、and tissue type metastasis of lymph node、Dukes' staging, only had significant differences with size;
2, Expression of bcl-2 had significant differences with metastasis of lymph node , Dukes' staging;
3, The expression of bax and the p53 protein had no significant differences with the clinical index of colorectal cancer;
4, The four gene expression had a positive rate between cancerous and adjacent tissues.
材料与方法:2007年12月至2008年3月,辽宁省肿瘤医院大肠科手术切除的大肠癌标本75例,男44例,女31例,年龄30-78岁,平均年龄54±4.6岁。术前明确临床分期,入院前均未行放、化疗及免疫等抗肿瘤治疗,无二次手术史。取癌组织和癌旁组织(距癌组织超过5 cm)各1份,经免疫组织化学方法(S-P法)检测癌组织及癌旁组织中c-erbB-2、bcl-2、bax和p53蛋白的表达。采用卡方检验分析实验数据,P<0.05认为有统计学差异。
结果:c-erbB-2蛋白主要表达在癌组织细胞膜,呈现明显棕黄色颗粒,其表达阳性率为50.7 % (38/ 75),癌旁组织无表达;bcl-2蛋白表达在癌组织及癌旁组织的细胞浆及细胞膜均呈阳性表达,表现为棕黄色颗粒,呈灶性或弥漫分布,其阳性率分别为61.3% (46/ 75), 10.7% (8/ 75);bax蛋白表达在癌组织及癌旁组织的细胞浆呈阳性表达,表现为细胞浆出现棕黄色颗粒,呈弥漫性或灶性分布,阳性率为46.7 % (35/ 75), 81.3% (61/ 75);p53蛋白主要表达于细胞核,呈清晰棕色,阳性率为52.0%(39/ 75),癌旁组织无表达。统计分析显示:c-erbB-2阳性表达与肿瘤的大小有显著性差异,与年龄、性别、肿瘤的组织类型、浸润深度、大体分型之间无差异; bcl-2蛋白表达与大肠癌患者的淋巴结转移、Dukes分期有显著性差异,与年龄、性别、肿瘤的组织类型、浸润深度、大体分型之间无差异;bax和p53蛋白表达与大肠癌的各项临床指标无显著差异。癌组织与癌旁组织间四种基因产物表达的差异均具有显著性。
结论:1,c-erbB-2阳性表达与肿瘤的大小有显著性差异,与年龄、性别、肿瘤的组织类型、浸润深度、大体分型之间无差异; 2,bcl-2蛋白表达与大肠癌患者的淋巴结转移、Dukes分期有显著性差异,与年龄、性别、肿瘤的组织类型、浸润深度、大体分型之间无差异;3,bax和p53蛋白表达与大肠癌的各项临床指标无显著差异;4,癌组织与癌旁组织间四种基因产物表达的差异均具有显著性。
Objective: To analyze the expression and clinical significance of c-erbB-2、bcl-2、bax and p53 in colorectal cancer by detecting their expression in cancerous and adjacent tissues(> 5cm from the cancerous tissue).
Methods: Examples of 75 cases of colorectal cancer who were treated in tumor hospital of Liaoning province from December 2007 to March 2008 ,Male 44,female 31,aged from 30 to78 years old and 54±4.6 for average. Each part respectively in cancerous and adjacent tissues (> 5cm from the cancerous tissue). The clinical stages were identified prior to operation. All patients have not received any treatment before. The expression of c-erbB-2、bcl-2, bax and p53 protein in all case were detected by immune histochemistry (S-P).The photographs of S-P were taken by microscope and the data were examined by chi-square test .
Results: The positive expression of c-erbB-2 protein in this group of 75 cases of cancerous tissues was 50.7 % (38/75), with performance of yellowish brown pellet in the cell membrane.adjacent tissues was negative;The positive expression of bcl-2 protein in this group of 75 cases of cancerous tissues was 61.3% (46/ 75), Adjacent tissues was 10.7% (8/ 75) ,with performance of yellowish brown pellet in cytoplasma and cell membrane, distribution of focus or diffuse; The positive expression of bax protein in this group of 75 cases of cancerous tissues was 46.7 % (35/ 75), adjacent tissues was 81.3% (61/ 75), existing in the form of the yellowish brown pellet in the cytoplasma, distribution of focus or diffuse. The positive expression of p53 protein in this group of 75 cases of cancerous tissues was 52.0%(39/ 75), adjacent tissues was negative ,mainly located in the cell nucleus,with clear brown color of cell nucleus; The statistical analysis demonstrated the expression of c-erbB-2 had no significant differences with age、gender、and tissue type, only had significant differences with size ( P<0.05 ) ;Expression of bcl-2 had significant differences with metastasis of lymph node, Dukes' staging(P<0.05); The expression of bax and the p53 protein had no significant differences with the clinical index of colorectal cancer (P > 0. 05); the four gene expressions had a positive rate between cancerous and adjacent tissues (P<0.05).
Conclusion:
1, The expression of c-erbB-2 had no significant differences with age、gender、and tissue type metastasis of lymph node、Dukes' staging, only had significant differences with size;
2, Expression of bcl-2 had significant differences with metastasis of lymph node , Dukes' staging;
3, The expression of bax and the p53 protein had no significant differences with the clinical index of colorectal cancer;
4, The four gene expression had a positive rate between cancerous and adjacent tissues.
引文
1. Peled A , ZiporiD, Roter V. Cooperation between p53-dependentand p53- independent apoptic pathway in myeloid cells. Cancer Res, 1996;56: 2148
2. Tsujitani S, ShiraiH, Tatebe S, et al. Apoptotic cell death and it’s relationship to carcinogenesis in colorectal carcinoma. Cancer,1996; 77 (8) : 1711
3.陈卫昌,林茂松,张宝峰,方静,周琼,胡莺,郜恒骏.结肠癌组织中p53和凋亡相关基因bcl-2,bax的表达极其临床意义.胃肠病学, 2006;11(7):395-396
4. Dougall WC, Qianx, Peterson Nc et al. The neu-oncogene:signal transduction pathways,transformation mechanisms and evolving therapies. Oncogene, 1994; 9:2109
5. Adell GC, Zhang H, Evertsson S, et al. Apoptosis in rectal carcinoma.prognosis and recurrence after preoperative radiot herapy [J]. Cancer, 2004; 91 (10):1870-1874
6. Feuerhake F, Unterberger P, Hofter EA, Cell turnover in apocrinemetaplasia of the human mammary gland epithelium: apoptosis, pro-liferation, and immunohistochemical detection of bcl-2, bax, EGFR, and c-erbB-2 gene products [J]. Acta Histochem, 2001;103(1):53-60
7. Eric R , Fearon ,Bert Vogelstein. A genetic model for colorectal tumorigensis. Cell ,1990;61 :759– 767
8.张常华,何裕隆,詹文华,等.多发性结肠癌中抑癌基因p53的表达与突变[J] .中华实用外科杂志,2005;3(22):305-306
9.金锡尊,焦成斌,姚海涛,等.胃癌p16、p53、c-erbB-2基因表达与淋巴结转移关系的研究[J] .中国实用外科杂志,2004;24(4):252
10. Natalia S ,Pellegata ,Ronald J ,et al . DNA damage and p53-mediated cell cycle arrest :a reevaluation. Proc Natl Acad Sci (USA) ,1996 ;93 :15209 -1521
11. Ullrich SJ ,Anderson CW, Mercer WE , et al . The p53 tumor suppressorprotein ,a modulator of cell proliferation. the Journal of Biological Chemistry ,1992;267 :15259– 15262
12. Vivian G. Evans. Multiple pathways to apoptosis. Cell Biology International, 1993; 17 :461– 476
13. Wang Y, Szekely L,Okan I, et al. Wild-type p53-triggered apoptosis is inhibital by bcl-2 in av-myc-induced T-cell lymphoma cell line. Oncogene,1993;8:3427-3431
14. Lotem J,Sachs L. Regulation by bcl-2,c-myc and of usceptibility to indcution of apoptosis by heat shook and cancer chemotherapy co-mpounds in differentiation competent and defective myeloid leukemia cells.Cell Growth Differentiation, 2003;3:41-47
15. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with complification of the Her-2/neu oncogene. Science,1987;235:177
16. Press MF, PikeMChazin VR et al. Her-2/neuexpression in node-negative breast cancer;direct tissue quantitation by computerized in age analysis and association of overexpression with increased risk of recurrent disease. Cancer Res, 1993;53:4960
17. TsujimotoY,CossmanJ,Jaffe E et al. Involvement of the bcl-2 gene in human follicular lymphoma.Science,1985,228:1440.
18.蔡永清,张跃伟,赵鲁茄,郭建波.大肠癌组织中Bcl-2表达与临床病理参数相关性的研究[J] .中华肿瘤防治杂志,2007;14(02):133-134
19. Bosari S,Moneghini L,Graziani D,et al.Prognostic aignificance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocar-cinoma.Int J Cancer,2001,74:534-540
20.王慧军,邓涛,沈志祥,等.大肠癌和大肠腺瘤cox-2和Bcl-2的基因表达及其意义.胃肠病学和肝病学杂志,2003; 12 (6)∶544-54
21.王举,忠霞,韩喜春,等.大肠癌及癌旁组织中抑凋亡基因bcl-2和促凋亡基因bax的表达及意义[J].中国普外基础与临床杂志,2002;9(4):252-254
22. Paradiso A, Simone G, Lena MD,et al. Expression of apoptosis- related markers and clinical outcome in patients withadvanced colorectal cancer[J] .Br J Cancer, 2001; 84(5):651-658
23.金树梅,戴洁,左东升,范英昌.Mdm2及p53与bcl-2在大肠良性和恶性病变中表达意义及相关性分析.中国肿瘤临床,2004;31(5):296-298
24. Cho Y, Gorina S, Jeffrey PD et al. Crystal structure of a p53 tumor suppressor-DNA. complex:Understanding tumorigenic mutation. Science, 1994 ; 265: 346
25.朱明华,Duan LX, Feitelson MA等.乙型肝炎病毒与肿瘤抑制基因p53相互作用的生物学功能及意义.病毒学报,1998;14 :10
26. Velculescu VE and EL-Deiry WS .Biological and clinical importance of the p53 tumor suppressor gene .Clinical Chem ,1996;42:6
27.雷厉.p53在大肠癌组织中的表达及临床意义.现代医院,2007;7(06):20-21
28. CHUNG D C, The genetic basis of colorectal cancer insight into critical pathways of tumor-genesis [J]. Gastrosenterology, 2000;119:854-865
29. POHIC,HAMBACH A,KRUIS W. Chronic inflammatory bowel disease and cancer [J]. Hepatogastroen terology, 2000;47:57-70
30.熊首先,朱尤庆,何军.MDM2和p53在大肠癌组织中的表达及意义.长江大学学报医学卷,2007;4,(1):11-12
1.陈卫昌,林茂松,张宝峰,方静,周琼,胡莺,郜恒骏.结肠癌组织中p53和凋亡相关基因bcl-2,bax的表达极其临床意义.胃肠病学,2006;11(7):395-396
2. Hastie ND,et al.Telomere reduction in human colorectal carcinoma and with ageing. Nature,1990;346:866
3. SlamonDJ,ClarkGM,WongSG et al.Human breast cancer:correlation of relapse and survival with complification of the Her-2/neu on cogene.Science,1987;235:177
4. PressMF,Pikemc,ChazinVR et al. Her-2/neuexpression in node-negative breast cancer;direct tissue quantitation by computerized in age analysis and association of overexpression with increased risk of recurrent disease.Cancer Res,1993;53∶4960
5. Dougall WC, Qianx, Peterson Nc et al.The neu-oncogene:signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene,1994;9:2109
6.吕柄蓉,檀碧波,韩杰,吕拍楠,石晓明,吴胜春.P53,C-erbB-2,rasP21,NM23-h1基因表达与大肠癌淋巴结转移的关系.河北医药, 2006;28(12):1136-1137
7. Pegran MD Pauletti G ,SlamonDJetal,Her-2/neu as a predictive mark of response to breast cancer therapey ,Breast Cancer Res,Trent 1998;52 :65
8.林志武,陈晓耕.进展期结直肠癌术前经直肠5 - Fu化疗的疗效观察[J] ..现代肿瘤医学,2004;12(3) :139-14
9. Palozza P, Serini S. Mechanism of activation of caspase cascade during beta carotene induced apoptosis in human tumor cells[J]. Nutr Cancer ,2003; 47:76-87
10. Tsujimoto Y,Cossman J,Jaffe E et al.Involvement of the bcl-2 gene in human follicular lymphoma.Science,1985;228:1440
11. Adams JM and Cory S. The Bcl-2 protein famlly : arbiters of cell survival .Science, 1998;281:1322
12. Yin XM, Oltvai ZN and Korsmeyer SJ. BH1 and BH2 domains of BCL-2 are required for inhibition of apoptpsis and heterodimerization with BAX. Nation, 1994; 369:321
13. Knudson CM, Korsmeyer SJ et al. Bax suppresses tumorigenesis and stimulates apoptosis in vivo .Nature, 1997;358:637
14. Kawasaki H ,Altieri DC ,Lu CD ,et al . inhibition of apoptosis by survivin predicts shortersurvival rates in colorectal cancer[J].Cancer Res ,1998;58 (22) :5071
15. Hwang T S, Han H S, Choi H K. Differential,stage-dependent expression of Hsp70, Hsp110 andBcl-2 in colorectal cancer [J], J Gastroenterol Hepatol, 2003;18(6):690-700
16. Scopa C D, Tsamandas A C, Zolota V. Potential role of bcl-2 and ki-67 expression and apotosis in colorectal carcinoma:clinicopathologic study [J]. Dig Dis Sci, 2003;48(10):1990-1997
17. Ilyas M ,Hao XP ,Wilkinson K ,et al . Loss of bcl22 expression correlates with tumour recurrence in colorectal cancer [J]. Gut ,1998;43 (3) :383.
18.王鲁建,宋敏等.非小细胞肺癌组织中bcl-2蛋白的表达与预后[J] .中华肿瘤防治杂志,2006;13(11):844-846
19. Sinicrope FA , Hart J , Hsu HA ,et al . Apoptotic and mitotic indices predict survival rates in lymp h node2negative colon carcinomas[J]. Clin Cancer Res ,1999;5 (7) :1793
20. Leahy DT ,Mulcahy HE ,ODonoghue DP ,et al . bcl-2 protein expression is associated with better prognosis in colorectal cancer[J]. Histopat hology ,1999;35 (4) :360
21. Bourdon JC, Deguin -Chambon D, Lelong JC et al. Further characterization of the p53 responsive element identification of new candidate genes for transactivation by p53 .Oncogene, 1997; 14:85
22. Wolkowicz R, Elkind NB, Ronen D et al.The DNA binding activity of wild type p53 is modulated by blocking its various antigenic epitopes . Oncogene, 1995; 10:1167
23. Marchetti A.Doglioni C, Barbareschi M et al. p21RNA and protein expression in non-small cell lung carcinomas: evidence of p53 independent expression and association with tumoral differentiation. Oncogene, 1996;12:1319
24.李收,孙雷璞,王立朴.肿瘤标记物与在肿瘤表达中相关性的研究进展.中国全科医学, 2006; 9:934-935
25. Greenblatt MS, Bennett WP, Hollstein M et al. Mutations in the p53 tumor suppressor gene :Clues to cancer etiology and molecular pathogenesis. Cancer Res, 1994;54:4855
26. Levine AJ, Momand J and Finlay CA. The p53 tumor suppressor gene . Nature, 1991; 352:453
27. Lane DP. P53, guardian of the genome. Nature, 1992; 358:15
28.欧玉荣,刘德純,张洪福.p27和p53基因在大肠癌中的表达及临床意义.中国组织化学与细胞化学杂志,2007;16(2):2-3
29. Michaeli M, Kotechetkov R, Vogei JV, et al.Cytomegalovirus infection blocksapoptosis in cancer cells. Cell Mol Life Sei, 2004;61:1307-1330
30. Bendardaf R, Larnlum H, Pyrhonen S. Prognostic and predietive molecular markers in colorectal carcinoma. Anticancer Res, 2004;24:2519-2530
31. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer[J]. Oncogene,2003;22(53):8581-8589
32.张生军,刘敏丽,魏晓丽,许静洪.Survivin基因在大肠癌中的表达及其临床意义.山西医科大学学报,2007;38(4):34-36
33. Altieri DC. Molecular circuits of apoptosis regulation and cell division control:the survivin paradigm[J]. J Cell Biochem,2004;92(4):656-663
34. Tanaka K ,Nagaoka S , Takemura T ,et al . Incidence of apoptosis increases with age in colorectal cancer [J]. Exp Gerontol ,2002;37(12) :1469
35. Sarela AI ,Scott N ,Ramsdale J ,etal . Immunohistochemical detection of the antiapoptosis protein , survivin ,predict s survival after curative resection of stageⅡcolorectal carcinomas[J]. Ann Surg Oncol ,2001;8 (4) :305
36. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and t herapy[J]. Trend Mol Med ,2001;7 :542
37. Kawasaki H ,Altieri DC ,Lu CD ,et al . inhibition of apoptosis by survivin predictsshortersurvival rates in colorectal cancer[J].Cancer Res ,1998 ;58 (22) :5071
38. Hemminiki K. Li X.Familial colorectal adenocarcinoma and hereditary nonpolyposis colorectal cancer: a national epidemiologyical study from Sweden . BR J Cancer,2001;84:969-974
2. Tsujitani S, ShiraiH, Tatebe S, et al. Apoptotic cell death and it’s relationship to carcinogenesis in colorectal carcinoma. Cancer,1996; 77 (8) : 1711
3.陈卫昌,林茂松,张宝峰,方静,周琼,胡莺,郜恒骏.结肠癌组织中p53和凋亡相关基因bcl-2,bax的表达极其临床意义.胃肠病学, 2006;11(7):395-396
4. Dougall WC, Qianx, Peterson Nc et al. The neu-oncogene:signal transduction pathways,transformation mechanisms and evolving therapies. Oncogene, 1994; 9:2109
5. Adell GC, Zhang H, Evertsson S, et al. Apoptosis in rectal carcinoma.prognosis and recurrence after preoperative radiot herapy [J]. Cancer, 2004; 91 (10):1870-1874
6. Feuerhake F, Unterberger P, Hofter EA, Cell turnover in apocrinemetaplasia of the human mammary gland epithelium: apoptosis, pro-liferation, and immunohistochemical detection of bcl-2, bax, EGFR, and c-erbB-2 gene products [J]. Acta Histochem, 2001;103(1):53-60
7. Eric R , Fearon ,Bert Vogelstein. A genetic model for colorectal tumorigensis. Cell ,1990;61 :759– 767
8.张常华,何裕隆,詹文华,等.多发性结肠癌中抑癌基因p53的表达与突变[J] .中华实用外科杂志,2005;3(22):305-306
9.金锡尊,焦成斌,姚海涛,等.胃癌p16、p53、c-erbB-2基因表达与淋巴结转移关系的研究[J] .中国实用外科杂志,2004;24(4):252
10. Natalia S ,Pellegata ,Ronald J ,et al . DNA damage and p53-mediated cell cycle arrest :a reevaluation. Proc Natl Acad Sci (USA) ,1996 ;93 :15209 -1521
11. Ullrich SJ ,Anderson CW, Mercer WE , et al . The p53 tumor suppressorprotein ,a modulator of cell proliferation. the Journal of Biological Chemistry ,1992;267 :15259– 15262
12. Vivian G. Evans. Multiple pathways to apoptosis. Cell Biology International, 1993; 17 :461– 476
13. Wang Y, Szekely L,Okan I, et al. Wild-type p53-triggered apoptosis is inhibital by bcl-2 in av-myc-induced T-cell lymphoma cell line. Oncogene,1993;8:3427-3431
14. Lotem J,Sachs L. Regulation by bcl-2,c-myc and of usceptibility to indcution of apoptosis by heat shook and cancer chemotherapy co-mpounds in differentiation competent and defective myeloid leukemia cells.Cell Growth Differentiation, 2003;3:41-47
15. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with complification of the Her-2/neu oncogene. Science,1987;235:177
16. Press MF, PikeMChazin VR et al. Her-2/neuexpression in node-negative breast cancer;direct tissue quantitation by computerized in age analysis and association of overexpression with increased risk of recurrent disease. Cancer Res, 1993;53:4960
17. TsujimotoY,CossmanJ,Jaffe E et al. Involvement of the bcl-2 gene in human follicular lymphoma.Science,1985,228:1440.
18.蔡永清,张跃伟,赵鲁茄,郭建波.大肠癌组织中Bcl-2表达与临床病理参数相关性的研究[J] .中华肿瘤防治杂志,2007;14(02):133-134
19. Bosari S,Moneghini L,Graziani D,et al.Prognostic aignificance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocar-cinoma.Int J Cancer,2001,74:534-540
20.王慧军,邓涛,沈志祥,等.大肠癌和大肠腺瘤cox-2和Bcl-2的基因表达及其意义.胃肠病学和肝病学杂志,2003; 12 (6)∶544-54
21.王举,忠霞,韩喜春,等.大肠癌及癌旁组织中抑凋亡基因bcl-2和促凋亡基因bax的表达及意义[J].中国普外基础与临床杂志,2002;9(4):252-254
22. Paradiso A, Simone G, Lena MD,et al. Expression of apoptosis- related markers and clinical outcome in patients withadvanced colorectal cancer[J] .Br J Cancer, 2001; 84(5):651-658
23.金树梅,戴洁,左东升,范英昌.Mdm2及p53与bcl-2在大肠良性和恶性病变中表达意义及相关性分析.中国肿瘤临床,2004;31(5):296-298
24. Cho Y, Gorina S, Jeffrey PD et al. Crystal structure of a p53 tumor suppressor-DNA. complex:Understanding tumorigenic mutation. Science, 1994 ; 265: 346
25.朱明华,Duan LX, Feitelson MA等.乙型肝炎病毒与肿瘤抑制基因p53相互作用的生物学功能及意义.病毒学报,1998;14 :10
26. Velculescu VE and EL-Deiry WS .Biological and clinical importance of the p53 tumor suppressor gene .Clinical Chem ,1996;42:6
27.雷厉.p53在大肠癌组织中的表达及临床意义.现代医院,2007;7(06):20-21
28. CHUNG D C, The genetic basis of colorectal cancer insight into critical pathways of tumor-genesis [J]. Gastrosenterology, 2000;119:854-865
29. POHIC,HAMBACH A,KRUIS W. Chronic inflammatory bowel disease and cancer [J]. Hepatogastroen terology, 2000;47:57-70
30.熊首先,朱尤庆,何军.MDM2和p53在大肠癌组织中的表达及意义.长江大学学报医学卷,2007;4,(1):11-12
1.陈卫昌,林茂松,张宝峰,方静,周琼,胡莺,郜恒骏.结肠癌组织中p53和凋亡相关基因bcl-2,bax的表达极其临床意义.胃肠病学,2006;11(7):395-396
2. Hastie ND,et al.Telomere reduction in human colorectal carcinoma and with ageing. Nature,1990;346:866
3. SlamonDJ,ClarkGM,WongSG et al.Human breast cancer:correlation of relapse and survival with complification of the Her-2/neu on cogene.Science,1987;235:177
4. PressMF,Pikemc,ChazinVR et al. Her-2/neuexpression in node-negative breast cancer;direct tissue quantitation by computerized in age analysis and association of overexpression with increased risk of recurrent disease.Cancer Res,1993;53∶4960
5. Dougall WC, Qianx, Peterson Nc et al.The neu-oncogene:signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene,1994;9:2109
6.吕柄蓉,檀碧波,韩杰,吕拍楠,石晓明,吴胜春.P53,C-erbB-2,rasP21,NM23-h1基因表达与大肠癌淋巴结转移的关系.河北医药, 2006;28(12):1136-1137
7. Pegran MD Pauletti G ,SlamonDJetal,Her-2/neu as a predictive mark of response to breast cancer therapey ,Breast Cancer Res,Trent 1998;52 :65
8.林志武,陈晓耕.进展期结直肠癌术前经直肠5 - Fu化疗的疗效观察[J] ..现代肿瘤医学,2004;12(3) :139-14
9. Palozza P, Serini S. Mechanism of activation of caspase cascade during beta carotene induced apoptosis in human tumor cells[J]. Nutr Cancer ,2003; 47:76-87
10. Tsujimoto Y,Cossman J,Jaffe E et al.Involvement of the bcl-2 gene in human follicular lymphoma.Science,1985;228:1440
11. Adams JM and Cory S. The Bcl-2 protein famlly : arbiters of cell survival .Science, 1998;281:1322
12. Yin XM, Oltvai ZN and Korsmeyer SJ. BH1 and BH2 domains of BCL-2 are required for inhibition of apoptpsis and heterodimerization with BAX. Nation, 1994; 369:321
13. Knudson CM, Korsmeyer SJ et al. Bax suppresses tumorigenesis and stimulates apoptosis in vivo .Nature, 1997;358:637
14. Kawasaki H ,Altieri DC ,Lu CD ,et al . inhibition of apoptosis by survivin predicts shortersurvival rates in colorectal cancer[J].Cancer Res ,1998;58 (22) :5071
15. Hwang T S, Han H S, Choi H K. Differential,stage-dependent expression of Hsp70, Hsp110 andBcl-2 in colorectal cancer [J], J Gastroenterol Hepatol, 2003;18(6):690-700
16. Scopa C D, Tsamandas A C, Zolota V. Potential role of bcl-2 and ki-67 expression and apotosis in colorectal carcinoma:clinicopathologic study [J]. Dig Dis Sci, 2003;48(10):1990-1997
17. Ilyas M ,Hao XP ,Wilkinson K ,et al . Loss of bcl22 expression correlates with tumour recurrence in colorectal cancer [J]. Gut ,1998;43 (3) :383.
18.王鲁建,宋敏等.非小细胞肺癌组织中bcl-2蛋白的表达与预后[J] .中华肿瘤防治杂志,2006;13(11):844-846
19. Sinicrope FA , Hart J , Hsu HA ,et al . Apoptotic and mitotic indices predict survival rates in lymp h node2negative colon carcinomas[J]. Clin Cancer Res ,1999;5 (7) :1793
20. Leahy DT ,Mulcahy HE ,ODonoghue DP ,et al . bcl-2 protein expression is associated with better prognosis in colorectal cancer[J]. Histopat hology ,1999;35 (4) :360
21. Bourdon JC, Deguin -Chambon D, Lelong JC et al. Further characterization of the p53 responsive element identification of new candidate genes for transactivation by p53 .Oncogene, 1997; 14:85
22. Wolkowicz R, Elkind NB, Ronen D et al.The DNA binding activity of wild type p53 is modulated by blocking its various antigenic epitopes . Oncogene, 1995; 10:1167
23. Marchetti A.Doglioni C, Barbareschi M et al. p21RNA and protein expression in non-small cell lung carcinomas: evidence of p53 independent expression and association with tumoral differentiation. Oncogene, 1996;12:1319
24.李收,孙雷璞,王立朴.肿瘤标记物与在肿瘤表达中相关性的研究进展.中国全科医学, 2006; 9:934-935
25. Greenblatt MS, Bennett WP, Hollstein M et al. Mutations in the p53 tumor suppressor gene :Clues to cancer etiology and molecular pathogenesis. Cancer Res, 1994;54:4855
26. Levine AJ, Momand J and Finlay CA. The p53 tumor suppressor gene . Nature, 1991; 352:453
27. Lane DP. P53, guardian of the genome. Nature, 1992; 358:15
28.欧玉荣,刘德純,张洪福.p27和p53基因在大肠癌中的表达及临床意义.中国组织化学与细胞化学杂志,2007;16(2):2-3
29. Michaeli M, Kotechetkov R, Vogei JV, et al.Cytomegalovirus infection blocksapoptosis in cancer cells. Cell Mol Life Sei, 2004;61:1307-1330
30. Bendardaf R, Larnlum H, Pyrhonen S. Prognostic and predietive molecular markers in colorectal carcinoma. Anticancer Res, 2004;24:2519-2530
31. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer[J]. Oncogene,2003;22(53):8581-8589
32.张生军,刘敏丽,魏晓丽,许静洪.Survivin基因在大肠癌中的表达及其临床意义.山西医科大学学报,2007;38(4):34-36
33. Altieri DC. Molecular circuits of apoptosis regulation and cell division control:the survivin paradigm[J]. J Cell Biochem,2004;92(4):656-663
34. Tanaka K ,Nagaoka S , Takemura T ,et al . Incidence of apoptosis increases with age in colorectal cancer [J]. Exp Gerontol ,2002;37(12) :1469
35. Sarela AI ,Scott N ,Ramsdale J ,etal . Immunohistochemical detection of the antiapoptosis protein , survivin ,predict s survival after curative resection of stageⅡcolorectal carcinomas[J]. Ann Surg Oncol ,2001;8 (4) :305
36. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and t herapy[J]. Trend Mol Med ,2001;7 :542
37. Kawasaki H ,Altieri DC ,Lu CD ,et al . inhibition of apoptosis by survivin predictsshortersurvival rates in colorectal cancer[J].Cancer Res ,1998 ;58 (22) :5071
38. Hemminiki K. Li X.Familial colorectal adenocarcinoma and hereditary nonpolyposis colorectal cancer: a national epidemiologyical study from Sweden . BR J Cancer,2001;84:969-974